Table 3.
Difference in proportion of patients with suspected disease among PET with different tracers and among patients with different prior treatment
| Variables | OR1 (95% CI) | p | Overall p |
|---|---|---|---|
| Suspect of Any Disease | |||
| CHOL | 1.0 | <0.001 | |
| ACET | 1.7 (0.88, 3.3) | 0.11 | |
| FACBC | 1.8 (0.79, 3.9) | 0.16 | |
| FDG | 0.40 (0.24, 0.66) | <0.001 | |
| PSMA | 3.6 (1.3, 10.2) | 0.014 | |
| RP3 | 1.0 | <0.001 | |
| RT3 | 4.1 (2.5, 6.7) | <0.001 | |
| Suspect of Extra-prostatic Disease | |||
| CHOL | 1.0 | <0.001 | |
| ACET | 0.75 (0.35, 1.6) | 0.48 | |
| FACBC | 0.47 (0.11, 2.0) | 0.31 | |
| FDG | 0.40 (0.24, 0.68) | 0.001 | |
| PSMA | 3.1 (1.4, 7.1) | 0.007 | |
| RP | 1.0 | 0.97 | |
| RT | 0.95 (0.61, 1.5) | 0.81 | |
| Suspect of Prostatic Only Disease | |||
| CHOL | 1.0 | 0.13 | |
| ACET | 2.4 (0.64, 8.9) | 0.19 | |
| FACBC | 2.9 (0.32, 26.1) | 0.34 | |
| FDG | 0.43 (0.17, 1.1) | 0.075 | |
| PSMA | 0.74 (0.23, 2.3) | 0.60 | |
| RP | 1.0 | <0.001 | |
| RT | 6.7 (3.8, 12.0) | <0.001 | |
| Suspect of Disease of Local Lesions2 | |||
| CHOL | 1.0 | 0.031 | |
| ACET | 2.2 (0.92, 5.0) | 0.076 | |
| FACBC | 5.0 (0.72, 34.6) | 0.10 | |
| FDG | 0.41 (0.16, 1.02) | 0.055 | |
| PSMA | 0.68 (0.23, 2.1) | 0.50 | |
| RP | 1.0 | <0.001 | |
| RT | 6.7 (3.8, 11.8) | <0.001 | |
| Suspect of Disease of Lymph Node Lesions2 | |||
| CHOL | 1.0 | <0.001 | |
| ACET | 1.3 (0.69, 2.4) | 0.43 | |
| FACBC | No observations | ||
| FDG | 0.40 (0.23, 0.70) | 0.002 | |
| PSMA | 2.2 (0.99, 5.1) | 0.053 | |
| RP | 1.0 | 0.26 | |
| RT | 1.3 (0.76, 2.1) | 0.37 | |
| Suspect of Disease of Bone Lesions2 | |||
| CHOL | 1.0 | 0.38 | |
| ACET | 0.78 (0.36, 1.7) | 0.53 | |
| FACBC | No observations | ||
| FDG | 0.62 (0.33, 1.2) | 0.15 | |
| PSMA | 1.5 (0.59, 3.7) | 0.40 | |
| RP | 1.0 | 0.90 | |
| RT | 1.1 (0.63, 2.0) | 0.68 |
Abbreviations: OR - Odds Ratio; CI - Confidence Interval; CHOL=11C- or 18F-Choline; ACET=11C-Acetate; FACBC=anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid; FDG=18F-fluorodeoxyglucose; PSMA=tracers targeting prostate-specific membrane antigen;
Odds ratios were estimated using mixed effects logistic regression models with different studies included as a random effect.
The analysis was on difference in the proportions of patients with suspected disease of local lesions, lymph node lesions, or bone lesions, regardless of the disease evaluation of any other lesions.
For all analyses on prior treatment, cohorts with mixed treatment were included in the models as separate categories, but ORs were not reported for the mixed group.